Status:
COMPLETED
D3-GHR Polymorphism and Turner Syndrome
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Turner Syndrome
Short Stature
Eligibility:
FEMALE
38-14 years
Brief Summary
The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in gir...
Eligibility Criteria
Inclusion
- Turner syndrome defined by a structural aberration or lack of the X chromosome.
- Growth velocity less than 2 cm/year at the time of final analysis (= final height).
Exclusion
- Age \<3.5 or \>14 years at start of GH therapy,
- GH peak serum levels \< 8 ng/ml in two independent tests,
- Thelarche at start or during the first year of treatment,
- Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
End Date :
May 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00443144
Start Date
May 1 2005
End Date
May 1 2007
Last Update
December 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University-Children's Hospital
Tübingen, Germany, 72076